Eli Lilly Q2 Revenue of $22.97B Significantly Beats Expectations, Full-Year Guidance Raised
Claire Weston
Eli Lilly posted Q2 revenue of $22.97 billion, beating Wall Street's $20.73 billion estimate by over $2 billion, driven by surging sales of weight-loss drug Zepbound and diabetes drug Mounjaro; the company raised full-year revenue guidance to $85–87 billion, sending shares up ~4% pre-market.
How big was the beat?
Revenue hit $22.97 billion, topping the Street's $20.73 billion estimate by 10.8%. Adjusted EPS came in at $8.38 versus expectations of $6.01 — nearly 40% above consensus.
This means → the market had already set a high bar, and Lilly cleared it by a wide margin. Demand for GLP-1 drugs — a new class of injectable and oral medicines that curb appetite and control blood sugar — is still accelerating, not plateauing.
Shares rose roughly 4% pre-market, an immediate vote of confidence.
How much did the two blockbusters sell?
Mounjaro (diabetes indication) generated $9.94 billion globally, up 91% year-on-year; international sales alone surged 172%.
Zepbound (weight-loss indication) posted $4.93 billion in U.S. revenue, up 44% year-on-year. Both figures exceeded analyst forecasts.
In plain terms = these two drugs combined for nearly $15 billion in a single quarter — roughly two-thirds of Lilly's total revenue. Lilly is now, in practice, a "GLP-1 company."
Why did international volume and price move in opposite directions?
Revenue outside the U.S. jumped 80% to $8.6 billion; volume grew 113%, but realized prices fell 36%.
This means → volume grew faster than prices dropped, so revenue still surged. The price decline was driven mainly by Mounjaro's inclusion in China's national insurance formulary — a classic volume-for-price trade to enter the world's largest incremental market.
This reflects Lilly's overseas playbook: secure reimbursement coverage first, scale the patient base, then let volume economics drive profit.
How did the new oral drug perform?
Foundayo, Lilly's oral GLP-1 drug approved by the FDA in April, contributed $98 million in its debut quarter — slightly below the ~$103 million analysts expected.
In plain terms = nearly $100 million in a first quarter on the market is solid in absolute terms, but the Street wanted more because an oral form (no injections) is expected to unlock a much larger patient pool.
This reflects that the oral GLP-1 ramp is still early-stage. The pace of uptake over the next few quarters will be the key metric to watch.
How much did full-year guidance move?
Full-year revenue guidance was raised to $85–87 billion, up from $82–85 billion. Adjusted EPS guidance was set at $35.50–36.50, versus $35.50–37.00 previously.
Underlying profit guidance rose by $2.78 per share at the midpoint, but was offset by $3.03 per share in acquisition-related charges this quarter — so the top end of EPS guidance actually ticked down.
This means → Lilly's confidence in its core business is rising, but it is simultaneously spending heavily on deals: this year it has acquired three vaccine companies and a psychedelic-drug developer, deploying GLP-1 cash flow to build future pipelines.
What matters most in the second half?
CEO Dave Ricks expects the global GLP-1 patient population to grow from roughly 20 million at end-2025 to about 30 million by end-2026 — a 50% increase in under a year.
U.S. Medicare — federal health insurance covering Americans aged 65 and older — began covering obesity drugs in early July. Both Lilly and rival Novo Nordisk stand to benefit.
In plain terms = two verification points will define the second half: how many patients actually start treatment once Medicare coverage is live, and how the competitive landscape in oral GLP-1 shakes out. These will determine whether Lilly's growth curve stays steep or begins to flatten.
Content is for reference only, not financial advice.